PT1140168E - Vacinacoes contra o cancro - Google Patents

Vacinacoes contra o cancro

Info

Publication number
PT1140168E
PT1140168E PT00906191T PT00906191T PT1140168E PT 1140168 E PT1140168 E PT 1140168E PT 00906191 T PT00906191 T PT 00906191T PT 00906191 T PT00906191 T PT 00906191T PT 1140168 E PT1140168 E PT 1140168E
Authority
PT
Portugal
Prior art keywords
against cancer
vaccinations against
vaccinations
prophylactically
medicament
Prior art date
Application number
PT00906191T
Other languages
English (en)
Portuguese (pt)
Inventor
Hans Loibner
Helmut Eckert
Original Assignee
Igeneon Krebs Immuntherapie F
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igeneon Krebs Immuntherapie F filed Critical Igeneon Krebs Immuntherapie F
Publication of PT1140168E publication Critical patent/PT1140168E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT00906191T 1999-01-13 2000-01-12 Vacinacoes contra o cancro PT1140168E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH5199 1999-01-13

Publications (1)

Publication Number Publication Date
PT1140168E true PT1140168E (pt) 2002-11-29

Family

ID=4178206

Family Applications (2)

Application Number Title Priority Date Filing Date
PT00906191T PT1140168E (pt) 1999-01-13 2000-01-12 Vacinacoes contra o cancro
PT02005394T PT1230932E (pt) 1999-01-13 2000-01-12 Uso de anticorpos para vacinacao contra o cancro

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT02005394T PT1230932E (pt) 1999-01-13 2000-01-12 Uso de anticorpos para vacinacao contra o cancro

Country Status (28)

Country Link
US (3) US7691372B2 (enExample)
EP (2) EP1140168B1 (enExample)
JP (1) JP4774551B2 (enExample)
KR (1) KR100771752B1 (enExample)
CN (1) CN1188169C (enExample)
AT (2) ATE219687T1 (enExample)
AU (1) AU768515B2 (enExample)
CA (1) CA2360382C (enExample)
CZ (1) CZ302801B6 (enExample)
DE (2) DE50009240D1 (enExample)
DK (2) DK1230932T3 (enExample)
EE (1) EE05474B1 (enExample)
ES (2) ES2177509T3 (enExample)
HK (1) HK1044487B (enExample)
HR (1) HRP20010526A2 (enExample)
HU (1) HU226150B1 (enExample)
ID (1) ID30223A (enExample)
IL (2) IL144265A0 (enExample)
IS (1) IS5998A (enExample)
MX (1) MXPA01007148A (enExample)
NO (1) NO329917B1 (enExample)
NZ (1) NZ512722A (enExample)
PL (1) PL201533B1 (enExample)
PT (2) PT1140168E (enExample)
SI (2) SI1230932T1 (enExample)
SK (1) SK286627B6 (enExample)
TR (1) TR200102034T2 (enExample)
WO (1) WO2000041722A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01007148A (es) * 1999-01-13 2002-03-27 Igeneon Krebs Immuntherapie Uso de anticuerpos para vacunacion anti-cancer.
AT410172B (de) 2000-03-21 2003-02-25 Igeneon Gmbh Verfahren zur herstellung einer vakzineformulierung
AT502293B1 (de) * 2002-05-15 2008-03-15 Igeneon Krebs Immuntherapie Immunogener, monoklonaler antikörper
AT500647A1 (de) * 2002-05-21 2006-02-15 Igeneon Krebs Immuntherapie Verwendung eines impfstoffes
AT500650B1 (de) 2003-04-17 2009-11-15 Altropus Gmbh Immunogener rekombinanter antikörper
AT500651B9 (de) * 2003-05-27 2010-04-15 Altropus Gmbh Aktiv immunisierender antikörper
JP2008505943A (ja) 2004-07-14 2008-02-28 イゲネーオン・クレープス−イムンテラピー・フォルシュングス−ウント・エントヴィックルングス−アクチェンゲゼルシャフト グリコシル化抗体
DE602004029455D1 (de) * 2004-07-20 2010-11-18 Altropus Gmbh Verwendung von Antikörpern in einer sehr geringen Dosis zur Impfung gegen Krebs
CN101355928B (zh) * 2005-04-26 2013-05-22 卫材R&D管理株式会社 用于癌症免疫疗法的组合物和方法
WO2007008943A2 (en) 2005-07-08 2007-01-18 Xencor, Inc. Optimized anti-ep-cam antibodies
EP1762575A1 (en) * 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
AT504231A1 (de) 2006-10-03 2008-04-15 Hans Dr Loibner Prädiktive parameter
BRPI0821165B8 (pt) 2007-12-07 2021-05-25 Nutricia Nv uso de uma composição
CA2744103C (en) * 2009-02-24 2018-01-02 Esbatech, An Alcon Biomedical Research Unit Llc Methods for identifying immunobinders of cell-surface antigens
US8887373B2 (en) 2012-02-24 2014-11-18 Covidien Lp Vessel sealing instrument with reduced thermal spread and method of manufacture therefor
US20140276968A1 (en) * 2013-03-14 2014-09-18 Ethicon, Inc. Applicator systems for surgical fasteners
US10196458B2 (en) * 2013-07-26 2019-02-05 The Regents Of The University Of California Anti-immunoglobulin E antibodies and methods of using thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341281C (en) * 1986-07-09 2001-08-07 Hubert J.P. Schoemaker Immunotherapy of tumor with monoclonal antibody against the 17-1a antigen
US5270202A (en) * 1989-11-03 1993-12-14 Syamal Raychaudhuri Anti-idiotypic antibodies to human melanoma-associated proteoglycan antigen
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5798100A (en) * 1994-07-06 1998-08-25 Immunomedics, Inc. Multi-stage cascade boosting vaccine
WO1997005597A1 (en) * 1995-07-31 1997-02-13 Litton Systems Canada Limited Flat panel pixel array incorporating photoconductive switches
EP0857176A1 (en) * 1995-10-25 1998-08-12 Centocor B.V. HUMAN EPITHELIAL ANTIGEN Ep-CAM DERIVED PEPTIDES AND THEIR USE
US6235280B1 (en) * 1996-04-12 2001-05-22 Malaya Chatterjee Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
IL121041A0 (en) * 1997-06-09 1997-11-20 Yeda Res & Dev Immunogenic compositions for induction of anti-tumor immunity
US6274143B1 (en) * 1997-06-13 2001-08-14 Malaya Chatterjee Methods of delaying development of HMFG-associated tumors using anti-idiotype antibody 11D10
ATE480566T1 (de) * 1998-06-15 2010-09-15 Quest Pharmatech Inc Immuntherapeutische zusammensetzung und verfahren zur behandlung von prostatakrebs
MXPA01007148A (es) * 1999-01-13 2002-03-27 Igeneon Krebs Immuntherapie Uso de anticuerpos para vacunacion anti-cancer.
WO2001087233A2 (en) * 2000-05-16 2001-11-22 New York University Anti-idiotypic antibody against fimh adhesin of uropathogenic type i-fimbriated escherichia coli, compositions and method of use thereof

Also Published As

Publication number Publication date
PL201533B1 (pl) 2009-04-30
US20100233178A1 (en) 2010-09-16
HK1044487B (zh) 2005-09-16
EP1230932A3 (de) 2003-11-26
SK9642001A3 (en) 2002-03-05
NO329917B1 (no) 2011-01-24
PT1230932E (pt) 2005-04-29
NO20013093L (no) 2001-09-10
US7691372B2 (en) 2010-04-06
CN1344167A (zh) 2002-04-10
NZ512722A (en) 2003-07-25
PL364747A1 (en) 2004-12-13
EE200100366A (et) 2002-10-15
MXPA01007148A (es) 2002-03-27
ES2177509T3 (es) 2002-12-16
EP1230932B1 (de) 2005-01-12
ES2236375T3 (es) 2005-07-16
HUP0200527A2 (en) 2002-06-29
ID30223A (id) 2001-11-15
NO20013093D0 (no) 2001-06-21
IL144265A (en) 2006-08-20
EP1140168A1 (de) 2001-10-10
KR100771752B1 (ko) 2007-10-30
SK286627B6 (sk) 2009-02-05
ATE219687T1 (de) 2002-07-15
IL144265A0 (en) 2002-05-23
EE05474B1 (et) 2011-10-17
TR200102034T2 (tr) 2001-11-21
US20120003232A1 (en) 2012-01-05
US8444974B2 (en) 2013-05-21
EP1140168B1 (de) 2002-06-26
CA2360382C (en) 2011-05-24
WO2000041722A1 (de) 2000-07-20
CA2360382A1 (en) 2000-07-20
CN1188169C (zh) 2005-02-09
HK1044487A1 (en) 2002-10-25
AU2796400A (en) 2000-08-01
JP4774551B2 (ja) 2011-09-14
DE50000243D1 (de) 2002-08-01
AU768515B2 (en) 2003-12-18
CZ302801B6 (cs) 2011-11-16
IS5998A (is) 2001-07-10
HU226150B1 (en) 2008-05-28
DK1230932T3 (da) 2005-04-25
JP2002534481A (ja) 2002-10-15
ATE286745T1 (de) 2005-01-15
KR20010101446A (ko) 2001-11-14
CZ20012581A3 (cs) 2002-01-16
HRP20010526A2 (en) 2002-08-31
SI1140168T1 (en) 2002-10-31
DK1140168T3 (da) 2002-09-30
DE50009240D1 (de) 2005-02-17
EP1230932A2 (de) 2002-08-14
US20070224202A1 (en) 2007-09-27
SI1230932T1 (en) 2005-06-30

Similar Documents

Publication Publication Date Title
ID30223A (id) Penggunaan antibodi untuk vaksinasi melawan kanker
TR200001253T2 (tr) Tümöre özel antijenler
CY1112753T1 (el) Θεραπευτικη αγωγη καρκινων του ανθρωπινου σωματος με τη χρηση toy ετ743
PT1223980E (pt) Utilizacao de inibidores de csf-1
DE60202877D1 (de) Gezieltes antikörper-verfahren
CY1110256T1 (el) Διαμεμβρανικο αντιγονο λεκτινης τυπου c εκφραζομενο σε καρκινο στον προστατη ανθρωπου και χρησεις αυτου
BR0210628A (pt) Liberação intradérmica de vacinas e agentes terapêuticos genéticos via microcânula
BR0108471A (pt) Objeto pré-formado para liberar um agente ativo a um paciente, e, processos de formação de um objeto pré-formado para liberar um agente e de liberação de um agente ativo a um paciente
CY1108765T1 (el) ΑΓΩΓΗ ME ΑΝΤΙΣΩΜΑΤΑ ANTI-ErbB2
DK1699480T3 (da) Allogent terapeutisk tumormiddel
NO20032027L (no) Effektive antitumorbehandlinger
CY1108377T1 (el) Χρηση ενωσεων 1-φαινυλο-3-διμεθυλαμινο-προπανιου για τη θεραπεια της ακρατειας ουρων
ATE407147T1 (de) Fab-fragmente humaner monoklonaler antikörper mit neutralisierender aktivität gegen das hcv e2 glycoprotein
PT1229936E (pt) Uso de anticorpos anti-idiotipicos como vacina contra o cancro
BR9604853A (pt) Vacinas contra chlamydia
DK1343896T3 (da) Lille syreoplöseligt sporeprotein og anvendelser deraf
CY1105142T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
AP2003002852A0 (en) Natural antibodies active against HIV virus
DK1150981T3 (da) Terapeutisk necleosidforbindelse
BR0007814A (pt) Uso de anticorpos para a vacinação contra câncer
ATE483473T1 (de) Verwendung von antikörpern in einer sehr geringen dosis zur impfung gegen krebs